Sanara MedTech Inc. (SMTI) is a company at the forefront of innovation in the healthcare and technology sector, focused on developing, marketing and distributing proprietary products in the wound and skin care market. Sanara’s mission is to improve patient outcomes by providing cutting-edge products and services to healthcare professionals and patients with chronic conditions.
Sanara MedTech Inc., based in Fort Worth, Texas, was initially incorporated in 1982. Over time, the company has evolved and refocused its operations to reduce healthcare costs, while improving the quality of life for patients. Today, SMTI is ground-breaking in its application of new treatment technologies, a significant shift from traditional wound care therapies.
The company's dedication to research, innovation, and application of unique problem-solving techniques, as well as its commitment to the medical and healthcare community and its patient-centric model, sets it apart within the specialized healthcare market. It operates through its Wholly-Owned Subsidiary, The Catalyst Health Science Group which focuses on healthcare products and services that increase positive clinical outcomes and dramatically reduce both the economic impact of care and patients' healing times.
Sanara's diverse product portfolio includes surgical and chronic wound care products which are innovative, clinically-tested, and FDA cleared. The products are designed to improve the wound healing process while reducing wound complications and the duration of wound care. These include BIAKŌS™ Antimicrobial Skin and Wound Cleanser, a solution with effectiveness against biofilms; HYCOL™ Hydrolyzed Collagen; and CellerateRx®, products used for various indications including trauma wounds and burns.
In the marketplace, Sanara MedTech is recognized for its commitment to addressing unmet medical needs with a focus on evidence-based healing solutions. The company's shares are publicly traded under the ticker symbol "SMTI".
SMTI is not just pioneering in product development but also in education and awareness. Sanara University, an education initiative by Sanara MedTech, is purposely designed to provide educational opportunities for healthcare professionals. It aims to share knowledge and research about products and techniques that can potentially improve patient outcomes.
In conclusion, Sanara MedTech Inc. stands as a leader and influencer in the medical technology industry. With its continuous innovation and commitment to patient care, SMTI provides pathbreaking solutions that are cost-effective, efficient, and accommodating of healthcare's changing roads. The growth and success of SMTI is testament to its dedication to creating a healthier and safer patient future.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Pomerantz LLP is investigating potential securities fraud claims against Sanara MedTech, Inc. (SMTI) on behalf of investors. The investigation stems from Sanara's November 2025 announcement to discontinue its Tissue Health Plus program, leading to a significant net loss and asset impairment charge. This news caused Sanara's stock price to drop by 24.7%.
Pomerantz LLP is investigating potential securities fraud claims against Sanara MedTech, Inc. (SMTI) following a significant stock drop. The investigation centers on Sanara's decision to discontinue its Tissue Health Plus (THP) program in November 2025, which resulted in a $31.2 million net loss from discontinued operations, primarily due to a $26.5 million asset impairment charge. Sanara's stock price subsequently fell by 24.7% on November 12, 2025.
Sanara MedTech Inc. (NASDAQ:SMTI) experienced a significant 42.8% decrease in short interest in July, totaling 216,090 shares, which represents 4.1% of outstanding shares and less than one day of average trading volume. This update follows a period of weakening analyst sentiment, with several downgrades leading to a consensus "Reduce" rating and an average price target of $35.00. The company also recently missed quarterly earnings expectations, reporting a loss of $0.05 per share against an anticipated $0.02 loss and revenue below estimates.
Walleye Capital LLC has made a new investment of $719,000 in Sanara MedTech Inc. (NASDAQ:SMTI), acquiring 30,465 shares, which represents about 0.33% of the company. Despite institutional investors collectively owning 8.10% of SMTI, analyst sentiment has weakened with several downgrades to "Hold" or "Neutral," and the company recently missed quarterly earnings and revenue estimates. Sanara MedTech specializes in medical technology for ear, nose, and throat healthcare, focusing on minimally invasive sinus dilation systems.
Sanara MedTech (NASDAQ:SMTI) reported its quarterly earnings, missing analyst expectations with a loss of $0.05 per share against an anticipated $0.02 loss, and revenue of $28.14 million below the $28.95 million estimate. The company posted a negative net margin of 31.23% and a negative return on equity of 3.19%, despite its shares trading near a 12-month high. Analyst sentiment has also shifted, with several firms downgrading the stock to "Hold" or "Neutral," resulting in a consensus "Reduce" rating and a $35 price target.
Sanara MedTech Inc. (SMTI) reported an 8.9% increase in revenue for Q2 2026, reaching $28.1 million, with gross profit rising to $26.2 million. Despite strong top-line growth, the company posted a net loss of $(0.05) per diluted share. The article also details hedge fund activity, with several institutions adjusting their positions in SMTI stock, and recent analyst price targets for the company.
Sanara MedTech Inc. (SMTI) reported an 8.9% increase in revenue to $28.1 million in Q2 2026, with gross profit rising to $26.2 million. Despite strong top-line growth, the company posted a net loss of $(0.05) per diluted share. Hedge funds showed mixed activity, and analysts set a median price target of $33.5 for SMTI stock.